CD38 and neoplasm: Daratumumab in combination with the Fc-silent CD47 blocking antibody hu5F9-IgG2σ achieved statistically significantly increases in phagocytosis of T-ALL cell lines and primary tumor cells compared to CD38 antibodies alone (Figure 3).